Cinctive Capital Management LP Has $11.03 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Cinctive Capital Management LP lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 166.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 148,923 shares of the medical research company’s stock after buying an additional 92,963 shares during the period. Cinctive Capital Management LP’s holdings in Edwards Lifesciences were worth $11,025,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth $26,000. Millstone Evans Group LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $30,000. Roble Belko & Company Inc acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $46,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $54,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EW. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Citigroup increased their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $71.77 on Wednesday. The firm has a 50 day simple moving average of $71.59 and a 200 day simple moving average of $70.59. The company has a market cap of $42.19 billion, a price-to-earnings ratio of 10.30, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares of the company’s stock, valued at $2,153,526.69. This trade represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 62,553 shares of company stock worth $4,513,064. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.